An efficient large-scale retroviral transduction method involving preloading the vector into a retronectin-coated bag with low-temperature shaking

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Dodo, Katsuyuki ^a   Chono, Hideto ^a   Saito, Naoki ^a   Tanaka, Yoshinori ^a   Tahara, Kenichi ^a   Nukaya, Ikuei ^a   Mineno, Junichi ^a  

^a TAKARA BIO INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN 4; MEMBRANE ANTIGEN; RETROVIRUS VECTOR;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; CANCER GENE THERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL POPULATION; CONTROLLED STUDY; EFFECTOR CELL; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LOW TEMPERATURE; PHENOTYPE; RETROVIRUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VALIDITY; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTACHMENT;

ADSORPTION; CD4-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; CELL LINE; COATED MATERIALS, BIOCOMPATIBLE; FIBRONECTINS; GENETIC THERAPY; HIV LONG TERMINAL REPEAT; HIV-1; HUMANS; PROMOTER REGIONS, GENETIC; RECEPTORS, ANTIGEN, T-CELL; RETROVIRIDAE; TEMPERATURE; TRANSDUCTION, GENETIC;

EID: 84898602795     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086275     Document Type: Article

References (49)

1. Yoder MC, Williams DA (1995) Matrix molecule interactions with hematopoietic stem cells. Exp Hematol 23: 961-967.
2. Ruoslahti E (1988) Fibronectin and its receptors. Annu Rev Biochem 57: 375-413.
3. Hynes RO (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
4. Kimizuka F, Taguchi Y, Ohdate Y, Kawase Y, Shimojo T, et al. (1991) Production and characterization of functional domains of human fibronectin expressed in Escherichia coli. J Biochem 110: 284-291.
5. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, et al. (1996) Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 2: 876-882. (Pubitemid 26296757)
6. Hanenberg H, Hashino K, Konishi H, Hock RA, Kato I, et al. (1997) Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 8: 2193-2206. (Pubitemid 28043557)
7. Chono H, Yoshioka H, Ueno M, Kato I (2001) Removal of inhibitory substances with recombinant fibronectin-CH-296 plates enhances the retroviral transduction efficiency of CD34(+)CD38(-) bone marrow cells. J Biochem 130: 331-334. (Pubitemid 32845685)
8. Pollok KE, Hanenberg H, Noblitt TW, Schroeder WL, Kato I, et al. (1998) High-efficiency gene transfer into normal and adenosine deaminase-deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. J Virol 72: 4882-4892. (Pubitemid 28215666)
9. Dardalhon V, Noraz N, Pollok K, Rebouissou C, Boyer M, et al. (1999) Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes. Hum Gene Ther 10: 5-14. (Pubitemid 29046141)
10. Markowitz D, Goff S, Bank A (1988) Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400-406. (Pubitemid 19037134)
11. Miller AD, Garcia JV, von Suhr N, Lynch CM, Wilson C, et al. (1991) Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J Virol 65: 2220-2224.
12. Pear WS, Nolan GP, Scott ML, Baltimore D (1993) Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90: 8392-8396. (Pubitemid 23277674)
13. Naviaux RK, Costanzi E, Haas M, Verma IM (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70: 5701-5705. (Pubitemid 26240755)
14. Yang S, Delgado R, King SR, Woffendin C, Barker CS, et al. (1999) Generation of retroviral vector for clinical studies using transient transfection. Hum Gene Ther 10: 123-132. (Pubitemid 29046152)
15. Le Doux JM, Morgan JR, Snow RG, Yarmush ML (1996) Proteoglycans secreted by packaging cell lines inhibit retrovirus infection. J Virol 70: 6468-6473. (Pubitemid 26266876)
16. Forestell SP, Bohnlein E, Rigg RJ (1995) Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Ther 2: 723-730. (Pubitemid 26043285)
17. Davis JL, Witt RM, Gross PR, Hokanson CA, Jungles S, et al. (1997) Retroviral particles produced from a stable human-derived packaging cell line transduce target cells with very high efficiencies. Hum Gene Ther 8: 1459-1467. (Pubitemid 27394001)
18. Seppen J, Kimmel RJ, Osborne WR (1997) Serum-free production, concentration and purification of recombinant retroviruses. Biotechniques 23: 788-790. (Pubitemid 27476123)
19. Bowles NE, Eisensmith RC, Mohuiddin R, Pyron M, Woo SL (1996) A simple and efficient method for the concentration and purification of recombinant retrovirus for increased hepatocyte transduction in vivo. Hum Gene Ther 7: 1735-1742. (Pubitemid 26340485)
20. Chuck AS, Palsson BO (1996) Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. Hum Gene Ther 7: 743-750. (Pubitemid 26125844)
21. Moritz T, Dutt P, Xiao X, Carstanjen D, Vik T, et al. (1996) Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88: 855-862. (Pubitemid 26333306)
22. Tonks A, Tonks AJ, Pearn L, Mohamad Z, Burnett AK, et al. (2005) Optimized retroviral transduction protocol which preserves the primitive subpopulation of human hematopoietic cells. Biotechnol Prog 21: 953-958. (Pubitemid 40772303)
23. Zhou P, Lee J, Moore P, Brasky KM (2001) High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. Hum Gene Ther 12: 1843-1855. (Pubitemid 32947228)
24. Quintas-Cardama A, Yeh RK, Hollyman D, Stefanski J, Taylor C, et al. (2007) Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. Hum Gene Ther 18: 1253-1260. (Pubitemid 350261967)
25. Chono H, Matsumoto K, Tsuda H, Saito N, Lee K, et al. (2011) Acquisition of HIV-1 resistance in T lymphocytes using an ACA-specific E. coli mRNA interferase. Hum Gene Ther 22: 35-43.
26. Chono H, Saito N, Tsuda H, Shibata H, Ageyama N, et al. (2011) In vivo safety and persistence of endoribonuclease gene-transduced CD4 + T cells in cynomolgus macaques for HIV-1 gene therapy model. PLoS One 6: e23585.
27. Okamoto M, Chono H, Kawano Y, Saito N, Tsuda H, et al. (2013) Sustained inhibition of HIV-1 replication by conditional expression of the E. coli-derived endoribonuclease MazF in CD4 + T cells. Hum Gene Ther Methods 24: 94-103.
28. Lee JT, Yu SS, Han E, Kim S, Kim S (2004) Engineering the splice acceptor for improved gene expression and viral titer in an MLV-based retroviral vector. Gene Ther 11: 94-99. (Pubitemid 38111393)
29. Okamoto S, Mineno J, Ikeda H, Fujiwara H, Yasukawa M, et al. (2009) Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res 69: 9003-9011.
30. Olah Z, Lehel C, Anderson WB, Eiden MV, Wilson CA (1994) The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter. J Biol Chem 269: 25426-25431. (Pubitemid 24336228)
31. Andreadis ST, Brott D, Fuller AO, Palsson BO (1997) Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5.5 to 7.5 hours. J Virol 71:7541-7548. (Pubitemid 27391695)
32. Bowerman B, Brown PO, Bishop JM, Varmus HE (1989) A nucleoprotein complex mediates the integration of retroviral DNA. Genes Dev 3:469-478.
33. Kildebeck E, Checketts J, Porteus M (2012) Gene therapy for primary immunodeficiencies. Curr Opin Pediatr 24: 731-738.
34. Mukherjee S, Thrasher AJ (2013) Gene therapy for PIDs: Progress, pitfalls and prospects. Gene 525: 174-181.
35. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117: 1466-1476. (Pubitemid 46871329)
36. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
37. June C, Rosenberg SA, Sadelain M, Weber JS (2012) T-cell therapy at the threshold. Nat Biotechnol 30: 611-614.
38. Hoxie JA, June CH (2012) Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med. doi:pii: a007179. 10.1101/cshperspect.a007179
39. Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, et al. (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol 10: 489-500.
40. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733.
41. Brentjens RJ, Curran KJ (2012) Novel cellular therapies for leukemia: CARmodified T cells targeted to the CD19 antigen. Hematology Am Soc Hematol Educ Program 2012: 143-151.
42. Restifo NP, Dudley ME, Rosenberg SA (2012) Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12: 269-281.
43. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, et al. (2006) Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103: 17372-17377. (Pubitemid 44788976)
44. Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, et al. (2013) Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121:1524-1533.
45. Wilen CB, Wang J, Tilton JC, Miller JC, Kim KA, et al. (2011) Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog 7: e1002020.
46. Maier DA, Brennan AL, Jiang S, Binder-Scholl GK, Lee G, et al. (2013) Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther 24: 245-258.
47. Yu SS, Nukaya I, Enoki T, Chatani E, Kato A, et al. (2008) In vivo persistence of genetically modified T cells generated ex vivo using the fibronectin CH296 stimulation method. Cancer Gene Ther 15: 508-516.
48. Chono H, Goto Y, Yamakawa S, Tanaka S, Tosaka Y, et al. (2011) Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation. J Biochem 149: 285-292.
49. Lamers CH, van Elzakker P, van Steenbergen SC, Sleijfer S, Debets R, et al. (2008) Retronectin-assisted retroviral transduction of primary human T lymphocytes under good manufacturing practice conditions: tissue culture bag critically determines cell yield. Cytotherapy 10:406-416. (Pubitemid 351983164)